Ghilardi, Guido
Fraietta, Joseph A. http://orcid.org/0000-0001-7900-8993
Gerson, James N.
Van Deerlin, Vivianna M. http://orcid.org/0000-0002-7400-9097
Morrissette, Jennifer J. D.
Caponetti, Gabriel C. http://orcid.org/0000-0002-7763-2458
Paruzzo, Luca
Harris, Jaryse C.
Chong, Elise A. http://orcid.org/0000-0001-8895-1625
Susanibar Adaniya, Sandra P. http://orcid.org/0000-0003-0703-2518
Svoboda, Jakub
Nasta, Sunita D.
Ugwuanyi, Ositadimma H.
Landsburg, Daniel J.
Fardella, Eugenio http://orcid.org/0009-0007-0273-1316
Waxman, Adam J.
Chong, Emeline R. http://orcid.org/0000-0002-0324-5367
Patel, Vrutti
Pajarillo, Raymone
Kulikovskaya, Irina
Lieberman, David B.
Cohen, Adam D. http://orcid.org/0000-0003-0939-3843
Levine, Bruce L. http://orcid.org/0000-0001-6971-8465
Stadtmauer, Edward A.
Frey, Noelle V.
Vogl, Dan T. http://orcid.org/0000-0002-2935-2566
Hexner, Elizabeth O. http://orcid.org/0000-0002-1125-4060
Barta, Stefan K.
Porter, David L.
Garfall, Alfred L.
Schuster, Stephen J. http://orcid.org/0000-0002-3376-8978
June, Carl H. http://orcid.org/0000-0003-0241-3557
Ruella, Marco http://orcid.org/0000-0003-4301-5811
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 PCA214278C, R01/37-CA262362-01A1)
Laffey-McHugh Foundation (No grant number, No grant number)
Society for Immunotherapy of Cancer (No grant number)
Leukemia and Lymphoma Society (2329-20)
Article History
Received: 19 December 2023
Accepted: 22 January 2024
First Online: 24 January 2024
Competing interests
: G.G. served as a scientific consultant for viTToria Biotherapeutics. M.R. holds patents related to CD19 CAR T cells, served as a consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Scaylite, Bayer and AbClon; and receives research funding from AbClon, NanoString, Oxford NanoImaging, viTToria Biotherapeutics, CURIOX and Beckman Coulter. M.R. is the scientific founder of viTToria Biotherapeutics. J.S. served as a consultant for Genmab, Adaptive, AstraZeneca, BMS, ADCT, Atara, Pharmacyclics and Seattle Genetics and received research funding from AstraZeneca, BMS, Incyte, Merck, Seattle Genetics, Pharmacyclics and TG Therapeutics. G.C.C. served as a consultant for DAVA Oncology and GLG consulting. E.A.C. served as a consultant for AstraZeneca, Novartis, Beigene, KITE and Juno/BMS and received research funding from Abbvie and Genentech/Roche. S.K.B. served as a consultant to Acrotech, Affimed, Kyowa Kirin, Daiichi Sankyo, Janssen and Seagen. S.D.N. received research funding from Pharmacyclics, Roche, Rafael and FortySeven/Gilead. J.D.L. received research funding from Curis, Takeda and Triphase and served on the Board of Directors, advisory committees and data and safety monitoring board for Incyte, ADCT, Karyopharm and Morphosis. S.J.S. served as a consultant to AstraZeneca, BeiGene, Celgene, Genentech, Genmab, Fate Therapeutics, Roche, Incyte, Juno Therapeutics, Legend Biotech, Loxo Oncology, MorphoSys, Mustang Biotech, Nordic Nanovector, Novartis and Regeneron; received research funding from AbbVie, Adaptive Biotechnologies, Celgene, DTRM, Genentech, Roche, Juno Therapeutics, Merck, Novartis, Incyte, Pharmacyclics and TG Therapeutics; received honoraria from Celgene and Novartis; and holds patents related to CD19 CAR T cells and autologous co-stimulated T cells. D.L.P. declares funding from the National Marrow Donor Program; membership on an entity’s Board of Directors or advisory committees of Kite/Gilead, Janssen, Genentech, DeCart, Sana Biotechnology, Verisimo and Novartis; is a current equity holder of the American Society for Transplantation and Cellular Therapy and Verismo; declares honoraria for Incyte; patents and royalties in Tmunity and Wiley and Sons Publishing. A.L.G. declares research support from Janssen, Novartis, Tmunity and CRISPR Therapeutics; consultancies/honoraria from Janssen, Novartis, BMS, GSK and Legend Bio; and DSMB membership for Janssen. C.H.J. and the University of Pennsylvania have patents pending or issued related to the use of gene modification in T cells for adoptive T cell therapy. C.H.J. is a co-founder of Tmunity, is a scientific co-founder and holds equity in Capstan Therapeutics, Dispatch Biotherapeutics and Bluewhale Bio. C.H.J. serves on the board of AC Immune and is a scientific advisor to BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta, Vittoria Bio and WIRB-Copernicus group. C.H.J. is an inventor on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and Kite and may receive license revenue from such licenses. J.A.F. is a member of the Scientific Advisory Boards of Cartography Bio and Shennon Biotechnologies and has patents, royalties and other intellectual property. B.L.L. reports personal fees from Akron, Avectas, Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, Thermo Fisher Pharma Services, UTC Therapeutics and Vycellix and is a co-founder and equity holder in Tmunity Therapeutics (acquired by Kite Pharma) and Capstan Therapeutics. N.V.F. declares an affiliation with Sana Biotechnology; consultancy roles for Novartis and Syndax Pharmaceuticals; and research funding from Kite Pharma. E.A.S. declares an affiliation with Oncopeptides; consultancy for Amgen, BMS Celgene, G.S.K., Janssen and AbbVie. E.O.H. declares an affiliation with Tmunity Therapeutics and research funding from Blueprint Medicines and PharmaEssentia; membership on an entity′s Board of Directors or advisory committees for Blueprint Medicines and PharmaEssentia. D.T.V. has received research funding from Takeda and Active Biotech and consulting fees from Takeda, Karyopharm, GSK, Genentech and Sanofi. A.D.C. is a scientific advisor for Janssen and BMS and has received research support and royalties from Novartis. The other authors declare no competing interests.